Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Gyre Therapeutics Inc shares valued at $20,560 were sold by Ma Songjiang on May 27 ’25. At $10.28 per share, Ma Songjiang sold 2,000 shares. The insider’s holdings dropped to 2,806,642 shares worth approximately $23.38 million following the completion of this transaction.
Also, Ma Songjiang sold 558 shares, netting a total of over 5,619 in proceeds. Following the sale of shares at $10.07 each, the insider now holds 2,806,084 shares.
Before that, Ma Songjiang had sold 2,000 shares from its account. In a trade valued at $21,940, the President traded Gyre Therapeutics Inc shares for $10.97 each. Upon closing the transaction, the insider’s holdings decreased to 2,000 shares, worth approximately $23.4 million.
As published in their initiating research note from Noble Capital Markets on March 11, 2025, Gyre Therapeutics Inc [GYRE] has been an Outperform. As of February 10, 2021, Piper Sandler has initiated its “an Overweight” rating for GYRE. Earlier on May 21, 2020, Raymond James initiated its rating. Their recommendation was “an Outperform” for GYRE stock.
Analyzing GYRE Stock Performance
On last trading session,, Gyre Therapeutics Inc [NASDAQ: GYRE] rose 2.97% to $8.33. During the last five days, there has been a drop of approximately -1.30%. Over the course of the year, Gyre Therapeutics Inc shares have dropped approximately -31.16%. Shares of the company reached a 52-week high of $13.75 on 03/07/25 and a 52-week low of $6.11 on 04/09/25.
Support And Resistance Levels for Gyre Therapeutics Inc (GYRE)
According to the 24-hour chart, there is a support level at 8.03, which, if violated, would cause prices to drop to 7.73. In the upper region, resistance lies at 8.59. The next price resistance is at 8.85. RSI (Relative Strength Index) is 45.77 on the 14-day chart, showing neutral technical sentiment.
